Nutraceuticals

Efficacy, Safety and Toxicity

2nd Edition - January 27, 2021
Editors: Ramesh C Gupta, Rajiv Lall, Ajay Srivastava
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 2 1 0 3 8 - 3
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 1 2 4 6 - 2

Nutraceuticals: Efficacy, Safety and Toxicity, Second Edition, brings together everything that is currently known about nutraceuticals and their potential toxic effects. The book… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Nutraceuticals: Efficacy, Safety and Toxicity, Second Edition, brings together everything that is currently known about nutraceuticals and their potential toxic effects. The book introduces readers to nutraceuticals, herbal medicines, Ayurvedic medicines, prebiotics, probiotics, adaptogens, and their uses and specific applications. This essential reference discusses the mechanism of action for the judicious use of these nutraceuticals and the best tools for their evaluation before detailing the safety and toxicity of nutraceuticals and interactions with other therapeutic drugs. Finally, and crucially, regulatory aspects from around the world are covered.

Completely revised and updated, this updated edition provides toxicologists, pharmacologists, pharmaceutical scientists, and those interested in medicinal plants and natural products with a comprehensive overview of the most effective tools upon which to evaluate the safety and toxicity of nutraceuticals, prebiotics, probiotics and alternative medicines.

Section I. Applications of nutraceuticals in common diseases and disorders

1. Nutraceuticals in central nervous system diseases: potential mechanisms of neuroprotection

2. Prevention of neurodegenerative disorders by nutraceuticals

3. Cognitive effects of nutraceuticals

4. Nutraceuticals in anxiety and stress

5. Countering cardiovascular diseases with nutraceuticals

6. Nutraceuticals for diabetes and glucose balance

7. Role of nutraceuticals in respiratory and allied diseases

8. Nutraceuticals in hepatic diseases

9. Nutraceuticals in renal diseases

10. Nutraceuticals in gastrointestinal disorders

11. Nutraceuticals in reproductive and developmental disorders

12. Nutraceuticals in ophthalmic diseases

13. Nutraceuticals in dermal diseases

14. Nutraceuticals in arthritis

15. Nutraceuticals in sports activities and fatigue

16. Role of nutraceuticals as adaptogens

17. Nutraceuticals for weight loss

18. Nutraceuticals in cancer prevention

19. Application of “nano” nutraceuticals in medicine
Section II. Models and mechanisms in evaluation of nutraceuticals

20. The biology of nutrients: genetic and molecular principles

21. Genomic and proteomic mechanisms and models in toxicity and safety evaluation of nutraceuticals

22. Transcriptomic profiling for safety and toxicity evaluation of
nutraceuticals

23. Target identification and polypharmacology of nutraceuticals

24. Systems pharmacology investigation of mechanism of action of nutraceuticals

25. Noninvasive in vivo optical imaging models for safety and toxicity testing

26. Flow cytometry and light-scattering techniques in evaluation of nutraceuticals

27. Zebrafish as a model system to evaluate the safety and toxicity of nutraceuticals

28. Caenorhabditis elegans: an elegant model organism for evaluating the neuroprotective and neurotherapeutic potential of nutraceuticals

29. Alternative in vitro models for safety and toxicity evaluation of nutraceuticals

30. Mitochondria as a target for safety and toxicity evaluation of nutraceuticals

31. Oxidative stress and excitotoxicity: antioxidants from nutraceuticals
Section III. Common nutraceuticals

32. Caffeine: an evaluation of the safety database

33. Biological activities and potential nanotechnological delivery of resveratrol

34. Melatonin: a safe nutraceutical and clinical agent

35. Standardized turmeric and curcumin

36. Curcuminoid-metal complexes for oxidative stress

37. Fenugreek: multiple health benefits

38. Cannabis sativa: an overview

39. Cannabidiol safety

40. St John’s wort (Hypericum perforatum L)

41. Green tea

42. Green coffee beans

43. Quercetin

44. German chamomile

45. Isoflavones: toxicological aspects and efficacy

46. Propolis

47. Bee products as nutraceuticals to nutraceuticals for bees

48. Ginkgo biloba

49. Chinese ginseng

50. Ashwagandha: multiple health benefits

51. Astaxanthin: health benefits and toxicity

52. Thymoquinone

53. Glucosinolates

54. Organosulfur compounds as nutraceuticals

55. Arginine and citrulline as nutraceuticals: efficacy and safety in diseases

56. Neem Extract

57. Spirulina

58. Garcinia cambogia

59. Vitamin E TPGS and its applications in nutraceuticals

60. Role of transferrin: an iron-binding protein in health and diseases

61. Glutamine supplementation: hope, hype, or stay tuned?

62. What to do with placenta after birth: is it a waste?

63. Chitin, chitosan, and their derivatives
Section IV. Prebiotics and probiotics

64. Prebiotics: safety and toxicity considerations

65. Probiotics: safety and toxicity considerations

66. Synbiotics: safety and toxicity considerations
Section V. Nutraceuticals in veterinary medicine

67. Nutraceuticals in animal health and diseases
Section VI. Toxicity and toxic interactions

68. Toxic contamination of nutraceuticals and food ingredients

69. Nutraceuticals and adverse outcome pathways

70. Interactions between nutraceuticals/nutrients and nutrients and therapeutic drugs

71. Genotoxicity evaluation of nutraceuticals
Section VII. Regulatory aspects

72. The regulatory framework for nutraceuticals: North America

73. Evaluation and regulation of food supplements: European perspective

74. Regulatory guidelines for nutraceuticals in India: an overview

75. Regulatory aspects of nutraceuticals: Chinese perspective

76. Uses and regulation of nutraceuticals: Australia and New Zealand

77. Regulatory aspects of nutraceuticals: Japanese perspective

78. Nutraceuticals: the Turkish perspective

Ramesh C Gupta

Dr. Ramesh C. Gupta, Professor & Head of Toxicology Department at Murray State university, is engaged in experimental brain research in relation to Alzheimer’s disease (AD) and pesticide toxicity. He has delivered lectures in Australia, Italy, Japan, Germany, France, Switzerland, Spain, Czech Republic, China, South Korea, and Sweden. He served the panels of NIH, CDC, NIOSH, and NAS. He has >350 publications to his credit, including seven major books with Elsevier: (1) Toxicology of Organophosphate and Carbamate Compounds, (2) Veterinary Toxicology: Basic and Clinical Principles, (3) Handbook of Toxicology of Chemical Warfare Agents, (4) Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology, (5) Reproductive and Developmental Toxicology, (6) Biomarkers in Toxicology and (7) Neutraceuticals. He is recipient of Murray State University's distinguished researcher award of the year-2006. He is a diplomate of American Board of Toxicology, and fellow of American College of Toxicology, American College of Nutrition, and Academy of Toxicological Sciences.

Affiliations and expertise

Professor and Head, Toxicology Department, Breathitt Veterinary Center, Murray State University, Hopkinsville, KY

Rajiv Lall

Mr. Rajiv Lall is the Founder and CEO of ProbioticSmart, LLC, a novel nutraceutical ingredients development company based on research and evidence-based science and Vets Plus, Inc., an international leader in the animal health industry. He graduated with two Masters degrees, the first in Botany from his native country of India, and the second in Pharmacognosy/Medicinal Chemistry from the University of Minnesota. His research focused on identifying, analyzing, and extracting natural ingredients from plants and plant tissue cultures that provide natural health and medicinal properties, as well as on enzymes in relation to cancer cells through animal cell cultures. Mr. Lall started his career in the human health food industry with an emphasis on probiotics. His relentless drive continues to champion both human and animal health through scientific research and the development of nutritional products and pharmaceuticals, and through these efforts he has obtained various patents and developed several hundred products. His company, Vets Plus, Inc. is a research and science-based product development company with a strong quality and manufacturing platform to support partners in Europe and around the world. Recent awards include the Pet Age Icon Award (2015), NASC Visibility Award (2015), and Menomonie Area Chamber of Commerce Business of the Year Award (2015). Vets Plus Inc. was also nominated for Wisconsin Manufacturer of the Year in 2015. In support of the animal health industry, Mr. Lall is now Founder and CEO of Noble Pharma, LLC, a pharmaceutical company in Menomonie, Wisconsin. Mr. Lall and his wife Swati are involved in philanthropic efforts and through that they have developed the Raj and Swati Lall Microbiology Laboratory at the University of Wisconsin-Stout in support of future scientists and business leaders and the community in Menomonie, Wisconsin.

Affiliations and expertise

Founder and CEO, ProbioticSmart, LLC and Vets Plus, Inc.

Ajay Srivastava

Dr. Ajay Srivastava is Chief Scientific Officer at Vets Plus Inc. and serves as an adjunct Faculty member at University of Wisconsin-Stout, Menomonie, US. He is specialized in preclinical and clinical product development and nutraceutical research. After receiving his BS in Biological Sciences, Dr. Srivastava earned his DVM from the School of Veterinary Medicine at GB Pant University of Agriculture and Technology, India, before pursuing his MS in Pharmacology. He completed his PhD in Neuropharmacology from All India Institute of Medical Sciences, New Delhi. After his post-doctoral training in preclinical drug development in neurological disorders, Dr. Srivastava became Senior Research Scientist of the Anticonvulsant Drug Development Program at the University of Utah, where he developed a novel animal model of pharmacoresistant epilepsy to screen potential antiepileptic drugs. He is one of the pioneer researchers who discovered the role of nutraceuticals resveratrol and melatonin in epilepsy. Dr. Srivastava has chaired various scientific sessions in AVMA and WVC meetings and has published several research articles in peer reviewed journals. He has contributed chapters in textbooks on epilepsy, toxicology and nutraceuticals.

Affiliations and expertise

Chief Scientific Officer, Vets Plus Inc.; Adjunct Faculty Member, University of Wisconsin-Stout, Menomonie, USA